Australia markets closed

Cochlear Limited (CHEOY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
75.39-0.47 (-0.62%)
At close: 03:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close75.86
Open76.47
Bid0.00 x 0
Ask0.00 x 0
Day's range74.91 - 76.47
52-week range63.18 - 94.21
Volume6,342
Avg. volume8,524
Market cap9.995B
Beta (5Y monthly)0.26
PE ratio (TTM)54.61
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.09 (1.45%)
Ex-dividend date25 Mar 2022
1y target estN/A
  • PR Newswire

    Cochlear announces 2022 winners of annual scholarships

    Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today the winners of the 20th annual Graeme Clark and the 11th annual Anders Tjellström Scholarships. The scholarships, named after two pioneers of the hearing implant industry, recognize Cochlear™ Nucleus® Implant, Cochlear Baha® System and Cochlear Osia® System recipients in the United States and Canada who uphold the Cochlear ideals of leadership and humanity, and demonstrate high academic achievement.

  • PR Newswire

    FDA approves Cochlear Nucleus Implants for unilateral hearing loss/single-sided deafness

    Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval of Cochlear™ Nucleus® Implants for the treatment of unilateral hearing loss (UHL)/single-sided deafness (SSD).

  • PR Newswire

    Cochlear announces FDA approval and FDA clearance of first-of-its-kind Remote Care capabilities for Nucleus and Baha Systems

    Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval and clearance in the last month for its Cochlear™ Remote Assist solution in the Nucleus® and Baha® Systems. The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.